TY - CHAP M1 - Book, Section TI - Acute Leukemia A1 - Damon, Lloyd E. A1 - Andreadis, Charalambos Babis A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2022 N1 - T2 - Current Medical Diagnosis & Treatment 2022 AB - Key Clinical Updates in Acute LeukemiaPatients with a FLT3 mutation benefit from the addition of the FLT3 kinase inhibitor midostaurin to their regimen.Patients with secondary AML (evolved from prior myelodysplastic or myeloproliferative disorders) or treatment-associated AML should receive the drug Vyxeos (a liposomal formulation of daunorubicin and cytarabine).Patients > 75 years of age who are not treated with initial curative intent can derive benefit from newer targeted agents, including the bcl2 inhibitor venetoclax added to a hypomethylating agent or low-dose cyatarabine, enasidenib (targeting IDH2 mutations), ivosidenib (targeting IDH2 mutations), or glasdegib. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1184166171 ER -